What do we know about the secretion and degradation of incretin hormones?
暂无分享,去创建一个
[1] K. Moley,et al. Studies with GIP/Ins cells indicate secretion by gut K cells is KATP channel independent. , 2003, American journal of physiology. Endocrinology and metabolism.
[2] J. Holst,et al. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. , 1996, Scandinavian journal of gastroenterology.
[3] P. Brubaker,et al. Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. , 2003, Endocrinology.
[4] H. Mekhjian,et al. Selective release of gastric inhibitory polypeptide by intraduodenal amino acid perfusion in man. , 1978, Gastroenterology.
[5] M. Namba,et al. Decrease in blood glucose and release of gut glucagon-like immunoreactive materials by bombesin infusion in the dog. , 1980, Endocrinologia japonica.
[6] B. Gallwitz,et al. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.
[7] A. Buchan,et al. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine , 1999, Cell and Tissue Research.
[8] B. Göke,et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.
[9] J. Dupré,et al. Effects of Ingestion of Triglyceride or Galactose on Secretion of Gastric Inhibitory Polypeptide and on Responses to Intravenous Glucose in Normal and Diabetic Subjects , 1978, Diabetes.
[10] J. Holst,et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM , 1996, Diabetologia.
[11] J. Holst,et al. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. , 2001, Diabetes.
[12] Bo Ahrén,et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. , 2002, Diabetes care.
[13] J. Polak,et al. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man , 1978, Histochemistry.
[14] M. Wolfe,et al. Release of gastric inhibitory peptide following a peptone meal in the dog. , 1982, Gastroenterology.
[15] J. Holst,et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.
[16] H. Vermeer,et al. Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man , 1992, European journal of clinical investigation.
[17] J. Holst,et al. Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1. , 1999, Endocrinology.
[18] H. Berthoud,et al. Lack of Gastric Inhibitory Polypepetide (GIP) response to vagal stimulation in the rat , 1982, Peptides.
[19] R. Pederson,et al. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.
[20] J. Brown,et al. Gastric inhibitory polypeptide and glucagon-like peptide-1(7-36) amide exert similar effects on somatostatin secretion but opposite effects on gastrin secretion from the rat stomach. , 1994, Canadian journal of physiology and pharmacology.
[21] J. Holst,et al. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. , 1996, Zeitschrift fur Gastroenterologie.
[22] Bo Ahrén,et al. 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels , 2022 .
[23] J. Holst,et al. All products of proglucagon are elevated in plasma from uremic patients. , 1992, The Journal of clinical endocrinology and metabolism.
[24] F. Carone,et al. Renal tubular processing of small peptide hormones. , 1982, The Journal of laboratory and clinical medicine.
[25] O. Flaten,et al. Beta-adrenergic stimulation and blockade of the release of gastric inhibitory polypeptide and insulin in man. , 1982, Scandinavian journal of gastroenterology.
[26] J. Holst,et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. , 1986, Endocrinology.
[27] B. Göke,et al. Endoproteolysis of Glucagon-like Peptide (GLP)-1(7–36) amide by Ectopeptidases in RINm5F Cells , 1997, Peptides.
[28] I. Valverde,et al. Renal catabolism of truncated glucagon-like peptide 1. , 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[29] R. Bruzzone,et al. Effect of bombesin on plasma insulin, pancreatic glucagon, and gut glucagon in man. , 1983, The Journal of clinical endocrinology and metabolism.
[30] J. Holst,et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. , 1996, The American journal of physiology.
[31] W. Meyers,et al. The hepatic extraction of gastric inhibitory polypeptide and insulin. , 1984, Endocrinology.
[32] Rolf Mentlein,et al. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.
[33] J. Holst,et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.
[34] A. Buchan,et al. Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose. , 1998, Endocrinology.
[35] P. Brubaker. Control of glucagon-like immunoreactive peptide secretion from fetal rat intestinal cultures. , 1988, Endocrinology.
[36] J. Cuber,et al. Stimulatory effect of beta-adrenergic agonists on ileal L cell secretion and modulation by alpha-adrenergic activation. , 1999, The Journal of endocrinology.
[37] B. Göke,et al. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. , 1995, The Journal of endocrinology.
[38] J. Brown,et al. Gastric Inhibitory Polypeptide: Its Physiologic Release and Insulinotropic Action in the Dog , 1975, Diabetes.
[39] D J Drucker,et al. Printed in U.S.A. Copyright © 1998 by The Endocrine Society Regulation of Glucagon-Like Peptide-1 Synthesis and , 2022 .
[40] Wang Wc,et al. Inhibition of somatostatin on glucose-induced release of gastric inhibitory polypeptide in rats. , 1987 .
[41] S. Werlin,et al. Effects of cholecystokinin-receptor blockade on pancreatic and biliary function in healthy volunteers. , 1991, Gastroenterology.
[42] G. Greenberg,et al. Neural Modulation of Glucose‐Dependent Insulinotropic Peptide (GIP) and Insulin Secretion in Conscious Dogs , 1994, Pancreas.
[43] A. Katz,et al. Glucagon metabolism in the rat. , 1978, The Journal of clinical investigation.
[44] T. O'dorisio,et al. Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs , 1987, Digestive Diseases and Sciences.
[45] J. Holst,et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.
[46] J. Holst,et al. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy , 1991, Digestive Diseases and Sciences.
[47] G. Greenberg,et al. Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release , 1997, Endocrine.
[48] K. Sirinek,et al. Chronic renal failure: effect of hemodialysis on gastrointestinal hormones. , 1984, American journal of surgery.
[49] J. Elovson. Biogenesis of plasma membrane glycoproteins. Purification and properties of two rat liver plasma membrane glycoproteins. , 1980, The Journal of biological chemistry.
[50] J. Holst,et al. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum , 2004, Regulatory Peptides.
[51] E. Mazzaferri,et al. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. , 1975, The Journal of clinical endocrinology and metabolism.
[52] G. Greenberg,et al. Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. , 2002, American journal of physiology. Endocrinology and metabolism.
[53] F. Reimann,et al. Glucose-sensing in glucagon-like peptide-1-secreting cells. , 2002, Diabetes.
[54] J. Holst,et al. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats , 1999, Diabetologia.
[55] J. Holst,et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.
[56] G. Greenberg,et al. The role of vagal integrity in gastrin releasing peptide stimulated gastroenteropancreatic hormone release and gastric acid secretion , 1985, Regulatory Peptides.
[57] J. Chayvialle,et al. Regulation of glucagon-like peptide-1-(7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon. , 1994, Endocrinology.
[58] P. Layer,et al. Ileal release of glucagon-like peptide-1 (GLP-1) , 1995, Digestive Diseases and Sciences.
[59] J. Holst,et al. Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.
[60] Tanya Hansotia,et al. Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. , 2002, Endocrinology.
[61] J. Holst,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes* , 2022 .
[62] L. B. Knudsen,et al. Structure-activity studies of glucagon-like peptide-1. , 1994, The Journal of biological chemistry.
[63] J. Holst,et al. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine , 2003, Regulatory Peptides.
[64] M. Nauck,et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.
[65] D. Marguet,et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[66] E. Mazzaferri,et al. Renal effects on serum gastric inhibitory polypeptide (GIP). , 1977, Metabolism: clinical and experimental.
[67] J. Chayvialle,et al. Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. , 1995, Endocrinology.
[68] John R. Christiansen,et al. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. , 1994, Scandinavian journal of gastroenterology.
[69] B. Göke,et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.
[70] J. Holst,et al. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.
[71] M. Nauck. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective , 1998, Acta Diabetologica.
[72] B. Göke,et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides , 1995, Regulatory Peptides.
[73] P. Brubaker,et al. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. , 1996, Endocrinology.
[74] J. Brown,et al. Release of gastric inhibitory polypeptide from cultured canine endocrine cells. , 1994, The American journal of physiology.
[75] F. Reimann,et al. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. , 2003, Diabetes.
[76] V. Mutt,et al. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP) , 1981, FEBS letters.
[77] J. Brown,et al. Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. , 1974, The Journal of clinical endocrinology and metabolism.
[78] J. Holst,et al. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. , 2001, Diabetes.
[79] D. Buckley. Analysis of the degradation of insulinotropin [GLP-1(7–37)] in human plasma and production of degradation resistant analogs , 1992, Regulatory Peptides.
[80] J. Holst,et al. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. , 2000, American journal of physiology. Endocrinology and metabolism.
[81] P. Brubaker,et al. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. , 1993, Endocrinology.
[82] J. Holst,et al. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. , 1998, Diabetes.
[83] J. Holst,et al. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. , 1997, The Journal of clinical endocrinology and metabolism.
[84] P. Brubaker,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Role of the Vagus Nerve in Mediating Proximal Nutrient- Induced Glucagon-Like Peptide-1 Secretion* , 2022 .
[85] M. Wolfe,et al. Regulation of glucose-dependent insulinotropic polypeptide release by protein in the rat. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[86] J. Holst,et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.
[87] J. Holst,et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. , 2004, Diabetes.
[88] M. Imamura,et al. Role of vagus nerve in secretion of gastric inhibitory polypeptide in dogs. , 1985, The Tohoku journal of experimental medicine.
[89] J. Holst,et al. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. , 1995, The American journal of physiology.
[90] I. Cleator,et al. Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances. , 1975, American journal of surgery.
[91] C. Beglinger,et al. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans. , 1991, The Journal of clinical endocrinology and metabolism.
[92] J. Holst,et al. Postprandial GLP-1, Norepinephrine, and Reactive Hypoglycemia in Dumping Syndrome , 2001, Digestive Diseases and Sciences.
[93] J. Holst,et al. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum A duodeno–ileal loop? , 2002, Regulatory Peptides.
[94] V. Marks,et al. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. , 1993, The Journal of endocrinology.
[95] J. Holst,et al. Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection. , 1993, Digestion.
[96] W. Creutzfeldt,et al. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution , 1980, Diabetologia.
[97] T. Hughes,et al. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. , 2002, The Journal of endocrinology.
[98] P. Brubaker,et al. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. , 2003, Canadian journal of physiology and pharmacology.
[99] G. Greeley,et al. Terbutaline, A β2-Adrenoreceptor agonist, inhibits gastric acid secretion and stimulates release of peptide YY and gastric inhibitory polypeptide in dogs , 1990, Digestive Diseases and Sciences.
[100] T. Dakka,et al. Peptide YY, Glucagon-Like Peptide-1, and Neurotensin Responses to Luminal Factors in the Isolated Vascularly Perfused Rat Ileum. , 1998, Endocrinology.
[101] P. Giacomoni,et al. Adrenergic modulation of gastric inhibitory polypeptide secretion in man , 1980, Regulatory Peptides.
[102] R. Jorde,et al. Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats. , 1981, Scandinavian journal of gastroenterology.
[103] S. Bloom,et al. A radioimmunoassay of gastric inhibitory polypeptide in human plasma. , 1980, The Journal of endocrinology.
[104] J. Holst,et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.
[105] T. Adrian,et al. Bombesin receptor subtype mediation of gastroenteropancreatic hormone secretion in rats , 1994, Peptides.